Compositions and methods for treating thyroid disease
The present disclosure relates to a compound and method of using such compound, preferably in the form of a dietary supplement that, when administered, is capable of treating thyroid disease and various thyroid-related disorders, such as Hashimoto's thyroiditis. The unique combination of the composition is preferably administered orally via acid resistant or enteric-coated capsule, soft gel or tablet. The composition is preferably comprised of at least Catalase, Reduced Glutathione, Acetylated Glutathione, DPP-IV protease enzyme, Pepsin, Bromelain, Pancreatin, Vitamin D, and Selenium. The composition can further comprise a palliative agent, and can be provided in specific dosages or administered in forms besides those listed above.
1. A method to treat a patient with Hashimoto's disease, comprising administering to said patient a composition comprising:
55 mcg of selenium;
250 mg of reduced glutathione;
50 mg of acetylated glutathione;
100 mg of dipeptidyl peptidase IV (DPP-IV) enzyme;
250 mg of bromelain;
250 mg of catalase;
20 mg of pepsin;
4000 IU of vitamin D3; and
200 mg of pancreatin enzyme.
2. The method of claim 1 , wherein the composition is administered to the patient in the form of a dietary supplement.
3. The method of claim 1 , wherein the composition is administered to the patient in the form of an acid resistant capsule.
4. The method of claim 1 , wherein the composition is administered to the patient orally in the form of a tablet.
5. The method of claim 1 , wherein the composition administered to the patient further comprises a palatability agent.
6. The method of claim 5 , wherein the palatability agent is at least one of a plant oil, plant hydrolysates, yeast hydrolysates, and combinations thereof.
7. The method of claim 1 , wherein the composition administered to the patient does not include gluten, wheat, egg, peanuts, tree nuts, dairy, sugar, corn, soy, fish and shellfish.